Free Daily Headlines :

  • COVID-19
  • Vaccine Info
  • Money
  • Politics
  • Education
  • Health
  • Justice
  • More
    • Environment
    • Economic Development
    • Gaming
    • Investigations
    • Social Services
    • TRANSPORTATION
  • Opinion
    • CT Viewpoints
    • CT Artpoints
DONATE
Reflecting Connecticut’s Reality.
    COVID-19
    Vaccine Info
    Money
    Politics
    Education
    Health
    Justice
    More
    Environment
    Economic Development
    Gaming
    Investigations
    Social Services
    TRANSPORTATION
    Opinion
    CT Viewpoints
    CT Artpoints

LET�S GET SOCIAL

Show your love for great stories and out standing journalism

Doubts about COVID-19 vaccine have spurred calls for transparency from Pfizer, other pharmaceuticals

  • Health
  • by Ana Radelat
  • September 17, 2020
  • View as "Clean Read" "Exit Clean Read"

Washington -– Seeking a competitive edge, drug companies zealously withhold details of clinical trials until they are completed. But Yale cardiologist Harlan Krumholz and many like-minded scientists say that veil of secrecy should be dropped, especially when it comes to trials of the COVID-19 vaccine.

“If people won’t take the vaccine because there’s no trust in the system, it won’t matter how good the vaccine is,” Krumholz said.

Krumholz, an advocate of “open science,” belongs to the Yale University Open Data Access (YODA) Project, organized by a group of scientists seeking the sharing of clinical research data.

He said transparency is especially important in the COVID-19 trials because the stakes are so high and because the process has been tainted by politics, especially White House pressure to speed a vaccine to market by the Nov. 3 election.

Concerns that production and testing of the vaccine are being rushed has caused public doubts. Polls show 20% of respondents say they won’t be inoculated and an even larger number say they aren’t sure whether to be. And a recent poll from the Kaiser Family Foundation found 62% of Americans said they worry the Food and Drug Administration would rush a vaccine without making sure it is safe and effective.

“There’s a hesitancy to use the vaccine. The trust is not there,” Krumholz said.

In the United States, Pfizer – which has a major research facility in Groton –  Moderna and AstraZeneca lead the global race to develop a COVID-19 vaccine. All have received taxpayer money.

Moderna was  awarded a $1.5 billion contract by the Department of Defense and the Department of Health and Human Services to manufacture and deliver 100 million doses of its COVID-19 vaccine;  HHS has said it will provide up to $1.2 billion to AstraZeneca to develop a potential vaccine at a laboratory at Oxford University, and Pfizer has been awarded a nearly $2 billion contract by the federal government to produce 100 million doses by December.

Dr. Harlan Krumholz, a cardiologist and health care researcher at Yale University, is seeking greater transparency in COVID-19 vaccine production and trials.

Questions about the transparency of the pharmaceuticals’ clinical trials, all in their final stages, were raised after AstraZeneca paused its trial earlier this month because a participant in Great Britain had experienced serious neurological symptoms.

The incident was not disclosed to the public. It was mentioned by AstraZeneca Chief Executive Pascal Soriot during a closed meeting organized by J.P. Morgan, and leaked by someone with the investment bank to the press. AstraZeneca has restarted its trial but has not released any details about the participant’s medical condition.

Pfizer, which has a trial site run by the Yale School of Medicine, and has partnered with German pharmaceutical BioNTech, made an announcement last weekend that it would expand its final trial from original plans to have 30,000 participants to 44,000.

“The proposed expansion would allow the companies to further increase trial population diversity, and include adolescents as young as 16 years of age and people with chronic, stable HIV (human immunodeficiency viruses), Hepatitis C, or Hepatitis B infection, as well as provide additional safety and efficacy data,” the company said.

Pfizer gave few other details about its revised plan.

However Moderna on Thursday took the unprecedented step of releasing a 135-page report on the protocols for its final clinical trial. The report said the pharmaceutical will make its first analysis of how its vaccine candidate has performed in that trail in December, but might not have enough information to make an accurate assessment until next spring.

Pfizer, AstraZeneca and seven other pharmaceutical companies working on a COVID-19 vaccine recently signed a pledge vowing to test potential vaccines for COVID-19 “in accordance with high ethical standards and sound scientific principles.”

Krumholz thinks that’s great, but said “words are not enough.”

“I think they should be sharing protocols and all the information they will submit to the Food and Drug Administration,” he said. “If people don’t trust the science, nothing good will come of it.”

To foster transparency, Krumholz would like the FDA to create a special advisory committee to review the pharmaceuticals’ work on a COVID-19 vaccine.

“What’s important is that these are people with unquestionable credentials,” he said.

Pfizer CEO Albert Bourla has said “transparency is a must.” But, by that he means Pfizer provides regular updates on its work on the vaccine to the FDA, not the public.

Pfizer said it has been in regular communication with FDA since the start of our study and is now sharing safety and efficacy data with the FDA’s Center for Biologics Evaluation and Research at “agreed upon study protocol intervals.”

Lawmakers seek transparency

This week, a group of eight Democratic senators, including Sens. Richard Blumenthal and Chris Murphy, asked FDA Commissioner Stephen Hahn to provide the public with information about the agency’s review of vaccine candidates.

“Full transparency throughout the review and authorization process is thus essential to countering real or perceived politicization and building public confidence in any approved vaccine,” the senators wrote Hahn. “Despite promises of transparency, many vaccine developers have not yet released their trial protocols, and in some cases they have disclosed information about the trials in closed-door meetings with investors that has not been made available to the general public.”

Besides making the data generated by clinical trials public, the senators have asked the FDA to make deliberations of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) open to the public. They also want the FDA to publish, in advance of a vaccine’s approval, details of the final trials including “how participants are recruited, how they will be monitored for severe side effects on an ongoing basis, and under what circumstances the trial would be terminated early.”

The senators asked the FDA to respond to a series of questions by Sept. 28.

Even if a vaccine that has proven safe and effective is developed quickly, Dr. Robert Redfield, the head of the Centers for Disease Control and Prevention, told a Senate panel on Wednesday that there will be “a very limited supply” and initial doses would be restricted to first responders, the elderly and others at greatest risk of death.

“If you’re asking me when is it going to be generally available to the American public, so we can begin to take advantage of vaccine to get back to our regular life, I think we’re probably looking at third, late second quarter, third quarter 2021,” Redfield said.

Sign up for CT Mirror's free daily news summary.

Free to Read. Not Free to Produce.

The Connecticut Mirror is a nonprofit newsroom. 90% of our revenue comes from people like you. If you value our reporting please consider making a donation. You'll enjoy reading CT Mirror even more knowing you helped make it happen.

YES, I'LL DONATE TODAY

ABOUT THE AUTHOR

Ana Radelat Ana has written about politics and policy in Washington, D.C.. for Gannett, Thompson Reuters and UPI. She was a special correspondent for the Miami Herald, and a regular contributor to The New York TImes, Advertising Age and several other publications. She has also worked in broadcast journalism, for CNN and several local NPR stations. She is a graduate of the University of Maryland School of Journalism.

SEE WHAT READERS SAID

RELATED STORIES
Lamont urges patience as residents flood online, phone systems in search of COVID vaccine appointments
by Jenna Carlesso, Mark Pazniokas and Dave Altimari

Residents reported long wait times on the phone, difficulty with online systems and appointments as far out as late April.

Who can get vaccinated against COVID in Connecticut, and when? Here’s what you need to know.
by Jenna Carlesso

Residents aged 55 and older can sign up starting March 1.

Medical providers are taking nature therapy seriously
by Jenifer Frank | C-HIT.ORG

In a time of social isolation and staying home, sometimes a walk in the park is the best medicine.

Have a case of a COVID variant? No one is going to tell you
by Christina Jewett and JoNel Aleccia | Kaiser Health News and Rachana Pradhan

Federal rules around who can be told about the variant cases are confusing, and tests have not been approved.

CT teachers are expected to get vaccinated for COVID at local clinics, but other options could cause problems
by Dave Altimari

School employees could end up on two lists, which means some vaccine might go to waste, officials said.

Support Our Work

Show your love for great stories and outstanding journalism.

$
Select One
  • Monthly
  • Yearly
  • Once
Artpoint painter
CT ViewpointsCT Artpoints
Opinion The marijuana legalization debate must be based on facts
by Will Jones III

In response to my earlier piece on why Connecticut lawmakers should reject marijuana commercialization,  Brendan Ruberry wrote a rebuttal that, on its face seems scathing, but to be clear, the attempted rebuttal falls flat and well off the mark.

Opinion Equity for women and girls essential to rebuild Connecticut’s economy
by Jennifer Steadman and Michelle Riordan-Nold

As Connecticut’s economy seeks to recover and rebuild, our success as a state will depend on how we respond to the disproportionate adverse impact of the coronavirus pandemic on women and girls, particularly women and girls of color.

Opinion Connecticut immigrants deserve health insurance
by Brooke Lifland, MD; Tanner Bommersbach, MD; Marco Ramos, MD PhD; and Eden Almasude, MD

Connecticut should pass House Bill 6334 to expand health insurance to all immigrants regardless of status. Our state wisely chose to protect the immigrant community by using Emergency Medicaid funds to cover expenses associated with COVID-19 testing and treatment for residents who were excluded from Medicaid based on their immigration status.

Opinion Truth or consequences: The impact of lie-based politics
by Charles M. Ericson and Sedona Ericson

A radio show by the above name, emceed by a man named Ralph Edwards, became a big hit starting in 1940. It eventually became a TV show, and all told, it lasted for decades. The format of the show was to be asked a question, and if it was not answered truthfully, the contestant submitted to undertaking a silly stunt of almost any kind. The show seemed reflective of a culture that valued untruth for perceived rewards, however trivial.

Artwork Grand guidance
by Anne:Gogh

In a world of systemic oppression aimed towards those of darker skintones – representation matters. We are more than our equity elusive environments, more than numbers in a prison and much more than victims of societal dispositions. This piece depicts a melanated young man draped in a cape ascending high above multiple forms of oppression. […]

Artwork Shea
by Anthony Valentine

Shea is a story about race and social inequalities that plague America. It is a narrative that prompts the question, “Do you know what it’s like to wake up in new skin?”

Artwork The Declaration of Human Rights
by Andres Chaparro

Through my artwork I strive to create an example of ideas that reflect my desire to raise social consciousness, and cultural awareness. Jazz music is the catalyst to all my work, and plays a major influence in each piece of work.”

Artwork ‘A thing of beauty. Destroy it forever’
by Richard DiCarlo | Derby

During times like these it’s often fun to revisit something familiar and approach things with a different slant. I have been taking some Pop culture and Art masterpieces and applying the vintage 1960’s and 70’s classic figures (Fisher Price, little people) to the make an amusing pieces. Here is my homage to Fisher -Price, Yellow […]

Twitter Feed
A Twitter List by CTMirror

Engage

  • Reflections Tickets & Sponsorships
  • Events
  • Donate
  • Newsletter Sign-Up
  • Submit to Viewpoints
  • Submit to ArtPoints
  • Economic Indicator Dashboard
  • Speaking Engagements
  • Commenting Guidelines
  • Legal Notices
  • Contact Us

About

  • About CT Mirror
  • Announcements
  • Board
  • Staff
  • Sponsors and Funders
  • Donors
  • Friends of CT Mirror
  • History
  • Financial
  • Policies
  • Strategic Plan

Opportunity

  • Advertising and Sponsorship
  • Speaking Engagements
  • Use of Photography
  • Work for Us

Go Deeper

  • Steady Habits Podcast
  • Economic Indicator Dashboard
  • Five Things

The Connecticut News Project, Inc. 1049 Asylum Avenue, Hartford, CT 06105. Phone: 860-218-6380

© Copyright 2021, The Connecticut News Project. All Rights Reserved. Website by Web Publisher PRO